Vismodegib
CAS 879085-55-9 8 FDA-DMF suppliersSmall Molecule
Overview
Vismodegib is a small molecule inhibitor of the Hedgehog signaling pathway, primarily used in the treatment of basal cell carcinoma. It works by binding to Smoothened, a component of the Hedgehog pathway, blocking the pathway’s signaling and leading to reduced tumor growth.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Vismodegib expires 15 Dec 2028. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologySkin CancerHedgehog Pathway Inhibition
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.